SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to a community divided between short-term concerns over token unlocks and strong belief in its advanced ZK-STARKs technology, quantum resistance, and growing ecosystem metrics like TVL, active users, and BTCFi integrations. Many argue the platform is currently undervalued given its consistent development and strategic positioning as essential infrastructure for Ethereum scaling.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE crypto is trending with high community engagement, fueled by speculation of a renewed 'meme season' and aspirations for significant price appreciation. Chatter reflects a mix of strong bullish predictions for a major rally and caution regarding volatility, frequently discussed in conjunction with broader crypto market trends.

Moo Deng

Recent volatile price swings and high trading volume are driving extensive community discussion around MOODENG CRYPTO. Investors are debating its potential for massive future pumps as a low market cap Solana meme coin, while also grappling with concerns over sharp drops.

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Eikon Therapeutics Inc.

Eikon Therapeutics is trending as its EIK1001 TLR7/8 agonist gains community attention for potential integration into NWBO's advanced combinatorial DCVax booster platform for personalized immunotherapies, fueled by discussions around recent insider buying.

USDX (Website: usdx.money | Twitter: @StablesLabs) is a synthetic USD stablecoin designed to provide stability without relying on traditional banking infrastructure. Backed by delta-neutral positions across multiple exchanges, USDX seamlessly bridges the gap between DeFi, CeFi, and TradFi. It enables DeFi users to access traditional delta-neutral strategies executed in CeFi platforms. As a crypto-native stablecoin, USDX offers a scalable, censorship-resistant, and highly stable solution for users looking to navigate the world of decentralized finance with confidence.

USDX Stablecoin

USDX Stablecoin is trending as community discussion focuses on its recent crash following the Balancer hack chaos, highlighting the fragility of DeFi stablecoins amidst ongoing efforts by major financial institutions to integrate crypto into traditional systems.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing a surge in attention driven by widespread community discussion and bullish sentiment regarding a "COEP Dogecoin merger" with 9,000 miners. The excitement is further amplified by general market optimism for meme coins and technical analysis pointing to bullish signals.

C.H. Robinson Worldwide, Inc. engages in the provision of freight transportation services and logistics solutions. It operates through the following segments: North American Surface Transportation (NAST), Global Forwarding, and All Other and Corporate. The NAST segment provides freight transportation services across North America through a network of offices in the United States, Canada, and Mexico. The Global Forwarding segment focuses on the global logistics services through an international network of offices in North America, Europe, Asia, Australia, New Zealand, and South America. The All Other and Corporate segment includes Robinson Fresh and Managed Services segments, as well as other surface transportation outside of North America and other miscellaneous revenues and unallocated corporate expenses. The company was founded by Charles Henry Robinson in 1905 and is headquartered in Eden Prairie, MN.

C.H. Robinson Worldwide, Inc.

C.H. Robinson Worldwide is drawing significant attention after a sector-wide sell-off driven by fears of AI disruption from a tiny challenger, sparking community debate over whether the reaction is overdone, especially given CHRW's existing AI leadership and recent insider purchases.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain (VET) is trending with community frustration peaking over its prolonged underperformance and recent executive departures, as discussions highlight skepticism about its "real utility" while some investors continue to accumulate in anticipation of a broader altcoin market rally.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining Corporation (CMCL) is actively discussed after a recent convertible note offering for its Bilboes Gold Project led to a significant share price pullback and concerns over dilution. While many investors express frustration that the stock has not mirrored gold's substantial rally, optimism remains high for CMCL's future given soaring gold prices and the project's potential to quadruple production.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors digest its Q4 earnings, which showed an EPS beat but revenue miss and cautious 2026 guidance, alongside a recent CEO transition. This sparks community debate over the stock's valuation and the sustainability of its recent 52-week highs amidst a rotation into defensive consumer staples.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's Why

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's What Happened...

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Time to Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Here's Why...

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Here's Why

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Should You Sell...

Biotech Stocks To Add to Your Watchlist - February 11th

Moderna, Danaher, Vertex Pharmaceuticals, Medpace, and Upstream Bio are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improved lung function. The company plans late-stage trials.read more...

<ul class="summary-bullets"><li>Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile.</li><li>Verekitug reduced asthma attacks by 56% with 100 mg, and 39% with 400 mg compared to placebo.</li><li>Upstream has begun planning Phase 3 studies.&nbsp;</li></ul>Shares of Upstream Bio Inc. (UPB) crashed more than 40% on Wednesday despite the company announcing positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.<h2 class="st-heading-2">Details Of The Test</h2>Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function. Patients received Verekitug every 12 weeks for the 100 mg dose or every 24 weeks for the 400 mg dose.&nbsp;Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.&nbsp;<h2 class="st-heading-2">Phase 3 Studies Update</h2>Upstream Bio structured the VALIANT trial with endpoints intended to support potential approval filings, and has begun planning Phase 3 studies in severe asthma and CRSwNP, with registrational trials expected after regulatory discussions.The results reportedly aligned exactly with Amgen’s (AMGN) Tezspire in effectiveness. The drug requires 210 milligrams every four weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/UPB">UPB</a> on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said the market reaction was ‘unwarranted’.<stembedurl>https://stocktwits.com/stjernerogvann/message/644653420</stembedurl>Another user saw a buying opportunity.<stembedurl>https://stocktwits.com/lordBrian/message/644666591</stembedurl>Year-to-date, the stock has declined more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Equity

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - Here's What Happened

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - What's Next...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat Ratings...

Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6% - Should You Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 4.6% - Should You Sell...

Upstream Bio (NASDAQ:UPB) Reaches New 52-Week High - Here's What Happened

Upstream Bio (NASDAQ:UPB) Reaches New 12-Month High - What's Next...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest UPB News

UPBUpstream Bio Inc.